The optimization of the distance between two key pharmacophore features within our first hit compounds 1a and 2a led to the identification of a new class of potent non-peptidic antagonists for the MCH-R1, based around 4-amino-2-cyclohexylaminoquinazolines. In particular, ATC0065 (2c), N2-[cis-4-({2-[4-Bromo-2-(trifluoromethoxy) phenyl] ethyl} amino) cyclohexyl]-N4, N4-dimethylquinazoline-2, 4-diamine dihydrochloride, bound with high ...